Summary
Background
Antenatal corticosteroids for pregnant women at risk of preterm birth
are among the most effective hospital-based interventions to reduce neonatal
mortality. We aimed to assess the feasibility, effectiveness, and safety of
a multifaceted intervention designed to increase the use of antenatal
corticosteroids at all levels of health care in low-income and middle-income
countries.
Methods
In this 18-month, cluster-randomised trial, we randomly assigned
(1:1) rural and semi-urban clusters within six countries (Argentina,
Guatemala, India, Kenya, Pakistan, and Zambia) to standard care or a
multifaceted intervention including components to improve identification of
women at risk of preterm birth and to facilitate appropriate use of
antenatal corticosteroids. The primary outcome was 28-day neonatal mortality
among infants less than the 5th percentile for birthweight (a proxy for
preterm birth) across the clusters. Use of antenatal corticosteroids and
suspected maternal infection were additional main outcomes. This trial is
registered with ClinicalTrials.gov,
number NCT01084096.
Findings
The ACT trial took place between October, 2011, and March, 2014
(start dates varied by site). 51 intervention clusters with 47 394
livebirths (2520 [5%] less than 5th percentile for
birthweight) and 50 control clusters with 50 743 livebirths (2258
[4%] less than 5th percentile) completed follow-up.
1052 (45%) of 2327 women in intervention clusters who delivered
less-than-5th-percentile infants received antenatal corticosteroids,
compared with 215 (10%) of 2062 in control clusters
(p<0·0001). Among the less-than-5th-percentile infants,
28-day neonatal mortality was 225 per 1000 livebirths for the intervention
group and 232 per 1000 livebirths for the control group (relative risk
[RR] 0·96, 95% CI
0·87–1·06, p=0·65) and suspected
maternal infection was reported in 236 (10%) of 2361 women in the
intervention group and 133 (6%) of 2094 in the control group (odds
ratio [OR] 1·67, 1·33–2·09,
p<0·0001). Among the whole population, 28-day neonatal
mortality was 27·4 per 1000 livebirths for the intervention group
and 23·9 per 1000 livebirths for the control group (RR 1·12,
1·02–1·22, p=0·0127) and suspected
maternal infection was reported in 1207 (3%) of 48 219 women in the
intervention group and 867 (2%) of 51 523 in the control group (OR
1·45, 1·33–1·58,
p<0·0001).
Interpretation
Despite increased use of antenatal corticosteroids in low-birthweight
infants in the intervention groups, neonatal mortality did not decrease in
this group, and increased in the population overall. For every 1000 women
exposed to this strategy, an excess of 3·5 neonatal deaths occurred,
and the risk of maternal infection seems to have been increased.
Funding
Eunice Kennedy Shriver National Institute of Child Health and Human
Development.